The Chloe Cole Act of 2026 gives children who received — and their parents — a federal private right of action against health care professionals, hospitals, and clinics that provided or participated in certain puberty‑delaying drugs, cross‑sex hormones, or surgeries. It defines covered interventions narrowly by purpose (to halt, delay, or alter sex‑linked development) but broadly by who "participates," and it places important procedural and evidentiary burdens on defendants.
This bill matters because it creates a new, nationwide civil liability regime for pediatric gender‑related medical care: it authorizes compensatory, non‑economic, and punitive damages, makes providers strictly liable for participation after enactment, and uses multiple interstate‑commerce hooks to secure federal jurisdiction. The combination of expansive definitions, strict liability, long limitation periods, and a prohibition on liability waivers would substantially raise litigation and insurance risk for clinicians and institutions that treat minors in this clinical space.
At a Glance
What It Does
The Act authorizes a federal civil suit by children subjected as minors — and their parents or guardians — against any provider who 'participates' in covered interventions (puberty blockers, sex hormones, certain surgeries). It makes damages available for economic, non‑economic, and punitive harm and, for participation after enactment, imposes strict liability unless a defendant proves a narrow exception by clear and convincing evidence.
Who It Affects
Pediatric endocrinologists, adolescent medicine specialists, surgeons, family physicians, hospitals and specialized clinics that provide gender‑related care for minors, as well as insurers and health systems that underwrite or contract for that care. Plaintiff attorneys and detransition service providers would also be directly involved.
Why It Matters
By defining 'sex' at conception and broadening 'participation,' the bill substitutes statutory standards for clinical judgment and creates a federal pathway for claims that can reach providers across state lines. That shifts the legal risk calculus for institutions and insurers and could change how pediatric gender‑related care is delivered or contracted.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act starts with definitions that matter for litigation more than for clinical practice: a 'covered intervention' is any treatment offered to someone under 18 with the explicit purpose of stopping, delaying, or altering development to make the body conform or not conform to sex, and the examples listed are puberty blockers, cross‑sex hormones, and surgeries that alter sexual organs or external appearance. The statute excludes care for verified disorders of sexual development and treatments for infections or organ‑system conditions; those exclusions are framed as affirmative defenses that defendants must prove.
It creates a federal private right of action. A child who underwent a covered intervention as a minor, or that child’s parents or legal guardians, may sue any provider — defined broadly to include anyone who prescribed, administered, planned, authorized, supervised, or knowingly coordinated such care.
Damages include economic recovery for costs of undoing or remediating harms, non‑economic damages for pain and suffering, and punitive damages subject to the usual clear‑and‑convincing standard.Two features change the litigation landscape. First, the bill imposes strict liability for participation that occurs after the law takes effect: if a provider’s participation after enactment is proved by clear and convincing evidence, liability follows without regard to prevailing standards of care.
Second, even when the alleged conduct predates enactment, the statute limits deference to historical standards of care where those standards were in 'serious, scientific, and medical dispute.' The Act also shifts burdens: exceptions to coverage are an affirmative defense and must be proven by the defendant by clear and convincing evidence.To keep these cases in federal court, the statute lists multiple commerce‑based jurisdictional hooks — travel, payments, mail or electronic communications, use of items that crossed state lines, and even occurrences within federal territories. The statute of limitations is unusually long: plaintiffs have until 25 years after their 18th birthday, or four years from incurring costs for detransition treatment, whichever is later.
Finally, the bill bars waivers of liability and requires courts to construe ambiguities against defendants, both of which increase plaintiffs’ leverage.
The Five Things You Need to Know
The Act defines 'covered interventions' to include puberty blockers, cross‑sex hormones (e.g.
testosterone, estrogen, anti‑androgens), and surgical procedures that alter sexual organs or external appearance for individuals under 18.
It grants a federal private right of action to children subjected as minors and to their parents or legal guardians against any health care professional, hospital, or clinic that 'participates' in a covered intervention.
Damages available include compensatory (economic) relief for costs to undo or ameliorate harms, non‑economic damages for pain and suffering, and punitive damages if the defendant acted maliciously, intentionally, fraudulently, or recklessly.
For participation occurring after enactment, the bill imposes strict liability; if a defendant claims an exclusion (e.g.
treatment for a disorder of sexual development), the defendant must prove that exception by clear and convincing evidence.
Federal jurisdiction is anchored broadly—travel, payments, communications, use of items that traversed interstate commerce, occurrences in federal territories, or any other effect on interstate commerce can bring a suit to federal court.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Identifies the Act as the 'Chloe Cole Act of 2026.' This is purely titular but important for citation. No operative effect beyond naming.
Definitions of child, covered interventions, and participation
This section sets the operative vocabulary for every claim. 'Child' is under 18. 'Covered intervention' is defined by purpose (to delay, halt, or change sex‑linked development) and by a three‑part list: puberty blockers, sex hormones, and surgeries to alter sexual organs or external appearance. 'Participate' reaches a wide range of clinical and supervisory conduct—prescribing, administering, authorizing, coordinating, or supervising—so non‑operating clinicians and institutional decision‑makers can be named defendants. The 'sex' definition is statutory and anchored to biological classification 'determined at the moment of conception,' a choice that will affect evidence strategies and recordkeeping.
Private right of action and damages
Subsection (a) authorizes the actual suit: the child or parents may bring a civil action in 'an appropriate district court of the United States' against any participant. Subsection (b) enumerates available remedies: compensatory damages for economic costs tied to remediation or detransition, non‑economic damages for emotional harm, and punitive damages where conduct meets the higher culpability standard. The damages language is broad, tying remedies directly to the costs and harms of reversing or treating the effects of an intervention.
Strict liability for post‑enactment participation and federal jurisdiction hooks
Subsection (c) imposes strict liability for participation that occurs after the Act’s effective date if proved by clear and convincing evidence; it also places the burden on defendants to prove applicability of statutory exceptions by the same high standard. Subsection (d) supplies multiple bases for federal jurisdiction tied to interstate commerce—travel, payments, communications, use of interstate items, and locations within federal territories—so many suits against out‑of‑state providers or clinics that use interstate networks can remain in federal court.
Rules of construction affecting waivers, ambiguities, and standards of care
This section forbids liability waivers, instructs courts to construe ambiguities against defendants, and limits deference to historical standards of care when those standards were in 'serious, scientific, and medical dispute' at the time of the intervention. It also clarifies that clinicians may still provide information about treatment options so long as that communication does not amount to 'participation.' These rules tilt procedural and interpretive questions in favor of claimants.
Statute of limitations and severability
Section 5 gives claimants an extended limitations window: actions may be brought within 25 years after the plaintiff’s 18th birthday or within 4 years of incurring detransition‑related expenses, whichever is later. Section 6 contains a standard severability clause designed to preserve the remainder of the Act if any provision is invalidated.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Children subjected to covered interventions and their parents — The bill creates a direct federal recovery path for economic and non‑economic harms tied to interventions performed while the individual was a minor, including funds to cover detransition care.
- Law firms and plaintiff litigators specializing in medical malpractice and civil rights — The statute opens a new source of federal claims with long limitation periods and procedural features (no‑waiver rule, ambiguity resolved against defendants) that can increase case viability.
- Providers of detransition or reconstruction services — Those offering corrective treatments may find new sources of compensation through damage awards and may see increased demand for their services.
Who Bears the Cost
- Pediatric endocrinologists, adolescent medicine clinicians, and surgeons who provide or supervise gender‑related care — They face increased exposure to lawsuits, potential for strict liability for conduct after enactment, and higher professional‑liability insurance costs.
- Hospitals, clinics, and health systems — Institutional defendants may see higher litigation and indemnity costs, changes to credentialing or service offerings, and potential reputational risk; systems that contract for such care will need to reassess contractor risk allocations.
- Private and public insurers — Insurers may face claims for coverage of damages tied to remediation and detransition, plus increased premiums or refusals that could alter the market for minors’ gender‑related care; ERISA and state‑law coverage disputes are likely.
Key Issues
The Core Tension
The central dilemma is between two legitimate goals: providing a robust remedy and deterrent for children harmed by irreversible interventions, and preserving medical judgment, clinical standards, and parental decision‑making without creating a legal regime so punitive or uncertain that it chokes off access to legitimate pediatric care. The bill leans toward accountability and remediation at the cost of legal certainty for clinicians and institutions.
The Act creates several knotty implementation problems. First, strict liability for participation after enactment paired with an extended limitations period and a no‑waiver rule exposes providers and institutions to large, potentially unpredictable awards.
Insurers will need to determine whether such claims fall within existing malpractice policies; coverage disputes could themselves spawn extensive litigation. Second, the broad 'participate' definition reaches non‑operational roles—supervising physicians, program directors, and administrative decision‑makers—which raises questions about proximate causation and the evidentiary showing required to prove 'intent' to alter development.
Third, the statutory definition of 'sex' as determined at conception and the bill’s instruction to resolve ambiguities against defendants press courts to adjudicate medical and scientific questions that are typically the province of clinical guidelines and state licensing authorities. The multiple interstate‑commerce jurisdictional hooks make federal court available but also open complex choice‑of‑law issues: how will courts apply state medical‑malpractice standards where federal rules narrow deference to those standards?
Finally, the bill’s retroactivity mechanics are uneven: it allows suits for interventions performed before enactment but makes strict liability applicable only to post‑enactment participation, producing difficult line‑drawing and evidentiary disputes about which legal standard applies to what conduct.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.